Trial Profile

A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary)
Indications Bronchial cancer; Duodenal cancer; Gastric cancer; Lung cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

21 Feb 2023 Have added bronchial and lung cancer for bronchopulmonary (Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise approximately 20% of all lung cancers )https://www.ncbi.nlm.nih.gov/pubmed/18473355.
10 Feb 2020 Status changed from active, no longer recruiting to completed.
20 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com